C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [ 99m Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.124.268169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Johanna S Enke und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Hyperaldosteronism, Receptors, CXCR4, Organotechnetium Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA.
Methods
Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [99mTc]Tc-pentixatec. Adrenal CXCR4 expression was analyzed by calculating lesion-to-contralateral ratios (LCRs). Imaging results were correlated to clinical information. Histopathology and clinical follow-up served as the standard of reference.
Results
Three subjects showed lateralization of adrenal tracer accumulation, with a mean maximum lesion-to-contralateral ratio of 1.65 (range, 1.52-1.70), which correlated with morphologic findings on CT. One individual underwent adrenalectomy and presented with complete biochemical and clinical remission at follow-up. Histopathologic workup confirmed unilateral aldosterone-producing adenoma. Conclusion: [99mTc]Tc-pentixatec scintigraphy with SPECT in patients with PA is feasible and might offer a valuable alternative to CXCR4-directed imaging with [68Ga]Ga-pentixafor PET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Department of Medicine IV, Ludwig Maximilians University Hospital Munich, Munich, Germany.
- Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Institute of Pathology, Ludwig Maximilians University Hospital Munich, Munich, Germany.
- Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany.
- Translational Radiopharmaceutical Sciences, Departments of Nuclear Medicine and Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Zitieren
APA
Enke, J. S., Ritzel, K., Asbach, E., Reitsam, N. G., Märkl, B., Knösel, T., Brüdgam, D., Kircher, M., Pfob, C. H., Bundschuh, R. A., Rinscheid, A., Nittbaur, B., Wienand, G., Schottelius, M., Reincke, M., Lapa, C., & Dierks, A. (2024). C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [ 99m Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268169
Vancouver
Enke JS, Ritzel K, Asbach E, Reitsam NG, Märkl B, Knösel T, et al. C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [ 99m Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.268169
BibTeX
@article{Enke2024,
author = {Enke, Johanna S and Ritzel, Kathrin and Asbach, Evelyn and Reitsam, Nic G and Märkl, Bruno and Knösel, Thomas and Brüdgam, Denise and Kircher, Malte and Pfob, Christian H and Bundschuh, Ralph A and Rinscheid, Andreas and Nittbaur, Bernd and Wienand, Georgine and Schottelius, Margret and Reincke, Martin and Lapa, Constantin and Dierks, Alexander},
title = {C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [ 99m Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.124.268169}
}
EUVIMED